Provectus Biopharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 0.827454 million compared to USD 1.03 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1985 USD | +1.07% | +1.90% | +106.77% |
1st Jan change | Capi. | |
---|---|---|
+106.77% | 83.28M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PVCT Stock
- News Provectus Biopharmaceuticals, Inc.
- Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023